Literature DB >> 27272267

Case Series With Histopathologic and Radiographic Analyses Following Failure of Fresh Osteochondral Allografts of the Talus.

Ryan Joseph Pomajzl1, Erin Ann Baker2, Kevin Charles Baker3, Mackenzie Marie Fleischer3, Meagan R Salisbury3, Dylan M Phillips3, Paul Thomas Fortin1.   

Abstract

BACKGROUND: Fresh osteochondral allografting of the talus is one treatment option for large chondral defects. Following positive early term results, failure rates of up to 35% have been reported. A retrieval study was performed to characterize failed talar allografts.
METHODS: Failed fresh osteochondral allografts of the talus were retrieved on revision. Cases of deep infection were excluded. After tissue fixation, samples were decalcified, embedded, and stained with Safranin-O/Fast Green, osteocalcin, tumor necrosis factor alpha (TNF-α), CD4, CD8, and CD68. Slides were graded according to the modified Mankin scoring system or severity scale. Medical record review was performed.
RESULTS: Eight allografts (7 patients) were retrieved from patients, following an average term of implantation of 31 months (range, 12-58). There were 3 types of allografts in this series (hemidome, n=5; segmental, n=2; bipolar, n=1). Reasons for transplantation were post-traumatic arthritis or osteonecrosis; reasons for revision were graft failure/collapse, nonunion, progressive arthritis, and/or pain. Prior to revision, all grafts exhibited collapse and subchondral lucencies. At the graft host interface, Safranin-O staining demonstrated substantial loss of sulfated glycosaminoglycans, Osteocalcin immunostaning was nearly absent, CD68 (indicating osteoclast activity) was predominantly exhibited, and CD4+ helper T cells as well as CD8+ cytotoxic T cells and NK cells-cell types commonly implicated in allogeneic organ transplant rejection-were found in high concentrations. TNF-α was present throughout the graft.
CONCLUSION: A histopathologic analysis of 8 retrieved, failed talar allografts was performed. Graft failure appeared to be primarily biologic, with an extensive loss of viable cartilaginous and osseous tissue at the graft-host interface. This study provides the first evidence of a potential CD4+ and CD8+ lymphocyte-mediated failure mechanism in fresh osteochondral allografts that were revised following collapse. LEVEL OF EVIDENCE: Level IV, case series.
© The Author(s) 2016.

Entities:  

Keywords:  collapse; failure; osteochondral allograft; talar allograft; talus

Mesh:

Year:  2016        PMID: 27272267     DOI: 10.1177/1071100716651963

Source DB:  PubMed          Journal:  Foot Ankle Int        ISSN: 1071-1007            Impact factor:   2.827


  5 in total

Review 1.  No superior surgical treatment for secondary osteochondral defects of the talus.

Authors:  Kaj T A Lambers; Jari Dahmen; Mikel L Reilingh; Christiaan J A van Bergen; Sjoerd A S Stufkens; Gino M M J Kerkhoffs
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-07-07       Impact factor: 4.342

2.  Clinical efficacy of the Ankle Spacer for the treatment of multiple secondary osteochondral lesions of the talus.

Authors:  Jari Dahmen; J Nienke Altink; Gwendolyn Vuurberg; Coen A Wijdicks; Sjoerd As Stufkens; Gino Mmj Kerkhoffs
Journal:  World J Orthop       Date:  2022-02-18

3.  Allograft Versus Autograft Osteochondral Transplant for Chondral Defects of the Talus: Systematic Review and Meta-analysis.

Authors:  Filippo Migliorini; Nicola Maffulli; Alice Baroncini; Jörg Eschweiler; Matthias Knobe; Markus Tingart; Hanno Schenker
Journal:  Am J Sports Med       Date:  2021-09-23       Impact factor: 7.010

4.  Clinical observation of biomimetic mineralized collagen artificial bone putty for bone reconstruction of calcaneus fracture.

Authors:  Yong-Xiong Pan; Guang-Gang Yang; Zhong-Wan Li; Zhong-Min Shi; Zhan-Dong Sun
Journal:  Regen Biomater       Date:  2018-02-08

5.  Fresh Osteochondral and Meniscus Allografting for Post-traumatic Tibial Plateau Defects.

Authors:  Pablo E Gelber; Juan I Erquicia; Eduard Ramírez-Bermejo; Oscar Fariñas; Juan C Monllau
Journal:  Arthrosc Tech       Date:  2018-05-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.